Digest Network Come funziona
Network
/
Società
At
Non verificato

Atamyo Therapeutics

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

4 comunicati stampa

Guarda tutti i comunicati
12/11/2024
Industria
Igiene alimentare
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
IND for ATA-200, a Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy Type 2C/R5 (LGMD2C/R5), cleared to proceed by FDA
Fonte
Atamyo Therapeutics
Emittente
Business Wire
1.00
0
30/09/2024
Eventi
Fiere
Industria
Biotecnologia
Tecnica
Igiene alimentare
Salute
Farmaceutica
Scienza
Tecnologie Varie
Medicina - Varie
Atamyo Therapeutics Observes LGMD Awareness Day with Updates on Key Milestones in its Clinical Development of Gene Therapies for Patients Suffering from Limb-Girdle Muscular Dystrophies
Fonte
Atamyo Therapeutics
Emittente
Business Wire
1.00
0
16/09/2024
Eventi
Industria
Scienza
Tecnica
Biotecnologia
Medicina - Varie
Farmaceutica
Salute
Atamyo Therapeutics to Provide Corporate Overviews and Updates on Its Pipeline Progress at 6 Upcoming Conferences in the US and Europe
Fonte
Atamyo Therapeutics
Emittente
Business Wire
1.00
0
04/09/2024
Multimedialità
Mercato del lavoro
Volontariato/Solidarietà/Non profit
Industria
Cardiologia
Biotecnologia
Farmaceutica
Salute
Associazioni/Professionisti
Medicina - Varie
The Dion Foundation and Atamyo Therapeutics Announce a Partnership to Expand into the US Atamyo’s Clinical Trial of ATA-200 Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2C/R5
Fonte
Atamyo Therapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0